SNGX
Soligenix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Significant Inflow of Main Funds
Ample Liquidity
Significant Revenue Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SNGX
Soligenix, Inc.
A late-stage biopharmaceutical company
29 Emmons Drive, Suite B-10, Princeton, NJ 08540
--
Founded in 1987, Soligenix, Inc., is a clinical-stage biopharmaceutical company focused on the development of products for the treatment of life-threatening side effects (still an unmet medical need) arising from the treatment of cancer and serious gastrointestinal diseases, as well as the development of a variety of biodefense vaccines and therapies.
Company Financials
EPS
SNGX has released its 2025 Q3 earnings. EPS was reported at -0.58, versus the expected -0.48, missing expectations. The chart below visualizes how SNGX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
